{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=5",
    "query": {
      "intervention": "IFN",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 878,
    "total_pages": 88,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T10:14:24.192Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00266318",
      "title": "Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Interferon Alfacon-1 and Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2005-12",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2008-04-17",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00266318"
    },
    {
      "nct_id": "NCT01376362",
      "title": "Topical Interferon Gamma for Macular Edema Secondary to Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anterior Uveitis",
        "Uveitis"
      ],
      "interventions": [
        {
          "name": "Interferon Gamma-1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2011-06",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376362"
    },
    {
      "nct_id": "NCT00000725",
      "title": "A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma, Kaposi",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        },
        {
          "name": "Interferon alfa-n1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": null,
      "completion_date": "1990-02",
      "has_results": false,
      "last_update_posted_date": "2021-11-03",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000725"
    },
    {
      "nct_id": "NCT01587690",
      "title": "Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2013-11-20",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01587690"
    },
    {
      "nct_id": "NCT01194037",
      "title": "A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection",
        "Genotype 1"
      ],
      "interventions": [
        {
          "name": "recombinant variant of interferon-alpha 2b",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HanAll BioPharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-06-23",
      "completion_date": "2011-11-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • National City, California • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01194037"
    },
    {
      "nct_id": "NCT03599453",
      "title": "Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Triple -Negative Breast Cancer",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Anatomic Stage IV Breast Cancer AJCC",
        "Progesterone Receptor Negative"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemokine Modulation Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2019-01-09",
      "completion_date": "2023-03-21",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03599453"
    },
    {
      "nct_id": "NCT00791271",
      "title": "Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alpha-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2008-09-02",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791271"
    },
    {
      "nct_id": "NCT03865212",
      "title": "Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Choroid Melanoma",
        "Metastatic Melanoma",
        "Metastatic Mucosal Melanoma",
        "Metastatic Uveal Melanoma",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2019-06-12",
      "completion_date": "2025-10-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 2,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03865212"
    },
    {
      "nct_id": "NCT02923466",
      "title": "Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Solid Tumour"
      ],
      "interventions": [
        {
          "name": "VSV-IFNβ-NIS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VSV-IFNβ-NIS and avelumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vyriad, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2017-04-17",
      "completion_date": "2022-04-22",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Minneapolis, Minnesota • Columbus, Ohio + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02923466"
    },
    {
      "nct_id": "NCT00250796",
      "title": "Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Thalidomide, alpha interferon",
          "type": "DRUG"
        },
        {
          "name": "Thalidomide, interferon, Octreotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2000-09",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2010-01-07",
      "last_synced_at": "2026-11-07T10:14:24.192Z",
      "location_count": 2,
      "location_summary": "Albuquerque, New Mexico • Santa Fe, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00250796"
    }
  ]
}